Lang James Paul

Lang James Paul is listed in filings as Director at Halozyme Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 7, 2026, including purchase activity. Recent filings connect the profile to Halozyme Therapeutics, Inc. (HALO), BioVie Inc. (BIVI), and OptimizeRx Corporation (OPRX). The current snapshot covers public activity from Jan 7, 2025 to May 7, 2026. Reported amounts are shown as $397.9K to $117.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.